keyword
MENU ▼
Read by QxMD icon Read
search

Trajenta

keyword
https://www.readbyqxmd.com/read/25297911/linagliptin-an-update-of-its-use-in-patients-with-type-2-diabetes-mellitus
#1
REVIEW
Kate McKeage
Linagliptin (Trajenta(®), Tradjenta(®)) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. A fixed-dose combination of linagliptin/metformin (Jentadueto(®)) is also available. This article reviews the pharmacology, therapeutic efficacy and tolerability of linagliptin in the management of type 2 diabetes, with the aim of updating its place in therapy based on recently published data. In randomized, controlled trials, oral linagliptin 5 mg once daily (or 2...
October 2014: Drugs
https://www.readbyqxmd.com/read/23638612/-oral-linagliptin-trajenta
#2
REVIEW
Daniel Duh, Indiana Tanret
No abstract text is available yet for this article.
March 2013: Journal de Pharmacie de Belgique
https://www.readbyqxmd.com/read/22913735/linagliptin-a-review-of-its-use-in-the-management-of-type-2-diabetes-mellitus
#3
REVIEW
Emma D Deeks
Linagliptin (Trajenta®, Tradjenta™, Trazenta™, Trayenta™) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once-daily use for the treatment of adults with type 2 diabetes mellitus, and a twice-daily fixed-dose combination of linagliptin/metformin (Jentadueto®) is also available. In this article, the pharmacological, clinical efficacy and tolerability data relevant to the use of linagliptin in patients with type 2 diabetes are reviewed...
September 10, 2012: Drugs
https://www.readbyqxmd.com/read/22482239/-linagliptin-trajenta-a-selective-dpp-4-inhibitor-with-limited-renal-elimination
#4
A J Scheen, L F Van Gaal
Linagliptin (Trajenta) is a selective inhibitor of dipeptidyl peptidase-4, an enzyme that degrades two incretin hormones, GLP-1 ("Glucagon-Like Peptide-1") and GIP ("Glucose-dependent Insulinotropic Polypeptide"). As other molecules belonging to this pharmacological class, linagliptin improves blood glucose control of type 2 diabetic patients, without increasing hypoglycaemic risk, without promoting weight gain and with a good clinical and biological tolerance profile. Both efficacy and safety have been demonstrated in randomized controlled trials as monotherapy or in combination with other glucose-lowering agents, independent of demographic or clinical patient's characteristics...
February 2012: Revue Médicale de Liège
https://www.readbyqxmd.com/read/22420306/linagliptin-a-novel-methylxanthin-based-approved-dipeptidyl-peptidase-4-inhibitor
#5
REVIEW
Ritesh Agrawal, Pratima Jain, S N Dikshit
Chemically, methylxanthine nucleus based Linagliptin (BI-1356, BI-1356-BS) is a dipeptidyl peptidase-IV inhibitor, which has been developed by Boehringer Ingelheim in association with Lilly for the treatment of Type-II Diabetes. Linagliptin was marketed by Lilly under the trade name Tradjenta and Trajenta. Linagliptin was approved as the once-daily dose by USFDA on 2 May 2011, for the treatment of Type-II Diabetes. Linagliptin 5mg once daily dose was approved based on a clinical trial program, which was conducted on approximately 4,000 adults with Type-II Diabetes...
June 2012: Current Drug Targets
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"